Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
Cabozantinib and atezolizumab were safely administered and showed promising ORR, and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation.
Authors
- Alejandro García‐Álvarez (ORCID: https://orcid.org/0000-0001-6948-0485)
- Marta Llanos (ORCID: https://orcid.org/0000-0002-4876-5075)
- Isabel Sevilla (ORCID: https://orcid.org/0000-0001-6942-159X)
- Alberto Carmona‐Bayonas (ORCID: https://orcid.org/0000-0002-1930-9660)
- Jorge Hernando (ORCID: https://orcid.org/0000-0002-0929-7360)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Carlos López (ORCID: https://orcid.org/0000-0002-8901-741X)
- Javier Molina‐Cerrillo (ORCID: https://orcid.org/0000-0003-4616-0598)
- Paula Jiménez‐Fonseca (ORCID: https://orcid.org/0000-0003-4592-3813)
- Vicente Alonso Orduña (ORCID: https://orcid.org/0000-0003-2280-1004)
- Rocio García‐Carbonero (ORCID: https://orcid.org/0000-0002-3342-397X)
- Inmaculada Gallego (ORCID: https://orcid.org/0000-0001-8134-4451)
- Jaume Capdevila (ORCID: https://orcid.org/0000-0003-0718-8619)
- Teresa Alonso‐Gordoa (ORCID: https://orcid.org/0000-0002-8966-7236)
- Ana Custodio (ORCID: https://orcid.org/0000-0003-1917-5479)
- Àlex Teulé (ORCID: https://orcid.org/0000-0003-0028-7200)
- Andrea Modrego Sánchez (ORCID: https://orcid.org/0000-0002-9000-6080)
- Marta Benavent Viñuales (ORCID: https://orcid.org/0000-0003-1268-4588)
- Beatriz Antón-Pascual (ORCID: https://orcid.org/0000-0001-9237-8614)
- Cinta Hierro (ORCID: https://orcid.org/0000-0002-0435-2172)
Institutions
- Hebron University (PS)
- Institut Català d'Ornitologia (ES)
- Hospital Universitario de Canarias (ES)
- Hospital Universitario La Paz (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital General Universitario Morales Meseguer (ES)
- Marqués de Valdecilla University Hospital (ES)
- Hospital Universitario 12 De Octubre (ES)
- Institut Català d'Oncologia (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Hospital Universitario Miguel Servet (ES)
- Centro Regional de Hemodonación (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Central de Asturias (ES)
- Badalona Serveis Assistencials (ES)
- Instituto de Investigación Sanitaria Aragón (ES)
- Duran i Reynals Hospital (ES)
- Hospital Municipal de Badalona (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2143
- Citations
- 3
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Exelixis
- Jazz Pharmaceuticals
- Novocure
- Les Laboratories Pierre Fabre
- Incyte
- Advanced Accelerator Applications
- Eisai
- Astellas Pharma
- Servier
- PharmaMar
- Ipsen